Newcardio Stock EBITDA
NewCardio fundamentals help investors to digest information that contributes to NewCardio's financial success or failures. It also enables traders to predict the movement of NewCardio Stock. The fundamental analysis module provides a way to measure NewCardio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NewCardio stock.
NewCardio | EBITDA |
NewCardio Company EBITDA Analysis
NewCardio's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current NewCardio EBITDA | (7.26 M) |
Most of NewCardio's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NewCardio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
NewCardio EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for NewCardio is extremely important. It helps to project a fair market value of NewCardio Stock properly, considering its historical fundamentals such as EBITDA. Since NewCardio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of NewCardio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of NewCardio's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
According to the company disclosure, NewCardio reported earnings before interest,tax, depreciation and amortization of (7.26 Million). This is 100.83% lower than that of the Health Care Technology sector and 101.13% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.19% higher than that of the company.
NewCardio EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NewCardio's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NewCardio could also be used in its relative valuation, which is a method of valuing NewCardio by comparing valuation metrics of similar companies.NewCardio is currently under evaluation in ebitda category among its peers.
NewCardio Fundamentals
| Return On Asset | -2.24 | ||||
| Operating Margin | (157.65) % | ||||
| Current Valuation | 49.72 K | ||||
| Shares Outstanding | 33.15 M | ||||
| Price To Sales | 0.21 X | ||||
| Revenue | 257.4 K | ||||
| Gross Profit | 105.1 K | ||||
| EBITDA | (7.26 M) | ||||
| Net Income | (11.5 M) | ||||
| Cash And Equivalents | 13.06 K | ||||
| Total Debt | 6.01 M | ||||
| Current Ratio | 0.01 X | ||||
| Book Value Per Share | (0.17) X | ||||
| Cash Flow From Operations | (4.56 M) | ||||
| Target Price | 1.25 | ||||
| Number Of Employees | 10 | ||||
| Beta | -120.6 | ||||
| Market Capitalization | 49.72 K | ||||
| Total Asset | 2.85 M | ||||
| Working Capital | (5.38 M) | ||||
| Current Asset | 35 K | ||||
| Current Liabilities | 5.41 M | ||||
| Net Asset | 2.85 M |
About NewCardio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NewCardio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NewCardio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NewCardio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether NewCardio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NewCardio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Newcardio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Newcardio Stock:Check out NewCardio Piotroski F Score and NewCardio Altman Z Score analysis. For more detail on how to invest in NewCardio Stock please use our How to Invest in NewCardio guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Health Care Technology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NewCardio. If investors know NewCardio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NewCardio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Revenue Per Share 0.008 | Quarterly Revenue Growth (0.90) | Return On Assets (2.24) |
The market value of NewCardio is measured differently than its book value, which is the value of NewCardio that is recorded on the company's balance sheet. Investors also form their own opinion of NewCardio's value that differs from its market value or its book value, called intrinsic value, which is NewCardio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NewCardio's market value can be influenced by many factors that don't directly affect NewCardio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NewCardio's value and its price as these two are different measures arrived at by different means. Investors typically determine if NewCardio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NewCardio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.